MedTrace Logo

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1049

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

albiglutide

albiglutide

DRUG

sitagliptin

sitagliptin

DRUG

glimepiride

Glimepiride

DRUG

metformin

Metformin

BIOLOGICAL

placebo albiglutide

placebo to match albiglutide

DRUG

placebo sitagliptin

placebo to match sitagliptin

DRUG

placebo glimepiride

placebo to match glimepiride

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-01-31
Completion
2013-04-30

Countries

  • United States
  • Albania
  • Germany
  • Hong Kong
  • Mexico
  • Peru
  • Philippines
  • Russia
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838903 on ClinicalTrials.gov